How should kidney function be monitored during Pirtobrutinib therapy?

Uric acid, potassium, phosphate, calcium and creatinine at initiation in high-burden disease; CBC and tumor burden trend; Blood pressure (class hypertension).

How can kidney injury from Pirtobrutinib be prevented?

Pre-treatment TLS risk assessment Hydration plus allopurinol (or rasburicase for high risk/elevated urate) Avoid concurrent nephrotoxins during debulking

Who is at higher risk of kidney injury from Pirtobrutinib?

High tumor burden / bulky or proliferative disease; Pre-existing CKD; Volume depletion; Inadequate TLS prophylaxis; Elevated baseline uric acid/LDH.

Back to explorer

Printable monograph

Non-covalent BTK inhibitor

Pirtobrutinib

Jaypirca · Pirto

Non-covalent BTK inhibitor · approved 2023 · 6 citations · FAERS AKI reporting ROR 2.88 (95% CI 1.78–4.66, 17 AKI reports)

Recent· through 2024

Fairly sourced6/9 · 6 signals

Met: 6 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 3y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2024
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A non-covalent BTK inhibitor for CLL/MCL — clearing high tumor burden raises tumor-lysis risk.

MildNon-covalent BTK inhibitor

Chronic lymphocytic leukemia / SLL (relapsed/refractory)Mantle-cell lymphoma (relapsed/refractory)

§01

Signature kidney injury

Signature lesion

Crystal / Obstructive Nephropathy

Direct nephrotoxicity is not characteristic. Tumor lysis syndrome is an identified risk when rapidly debulking high-burden lymphoid malignancy; renal-specific incidence is low and not well quantified. BTK inhibitors as a class are also associated with hypertension and bleeding/atrial fibrillation (non-renal).Source: Mato et al., N Engl J Med 2023 (BRUIN)

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Tumor lysis early after initiation in high-burden disease (first cycle), usually a single early event.

Distilled from: “Early after initiation in high-burden disease (first cycle); TLS is usually a single early event.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Crystal / Obstructive Nephropathy#1 · Signaturequalitative — no citable incidence
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityReversible

Evidence6 citations

Nephron map

Vasculature / Endothelium

Distal Tubule / Collecting Duct

Tubular LumenThe urine flow path

Crystal / Obstructive Nephropathy

Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.

§03

Kidney injury

Mechanism of kidney injury

Effective cytoreduction of bulky leukemia/lymphoma can precipitate tumor lysis syndrome — release of intracellular potassium, phosphate, and purines (metabolized to uric acid) with intratubular precipitation of uric-acid and calcium-phosphate crystals causing obstructive crystalline AKI, compounded by renal vasoconstriction. Associated volume shifts and reduced intake add a pre-renal component. The drug itself is not a recognized tubular toxin.

Clinical presentation

TLS labs — hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia — with rising creatinine, typically early after initiation in high-burden disease. Outside TLS, renal function is generally stable.

Management

Standard TLS management: aggressive IV hydration, rasburicase for hyperuricemia, correction of hyperkalemia/hyperphosphatemia/hypocalcemia, and renal replacement therapy if refractory. Supportive AKI care; the drug can usually be continued once TLS is controlled.Lesion-level management framework

Risk factors

High tumor burden / bulky or proliferative disease
Pre-existing CKD
Volume depletion
Inadequate TLS prophylaxis
Elevated baseline uric acid/LDH

Prevention

Pre-treatment TLS risk assessment
Hydration plus allopurinol (or rasburicase for high risk/elevated urate)
Avoid concurrent nephrotoxins during debulking

Anticancer mechanism· how it treats cancer

Reversible, non-covalent (non-C481-dependent) Bruton tyrosine-kinase inhibitor that retains activity against covalent-BTK-inhibitor-resistant disease, including C481S mutants. Approved for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle-cell lymphoma.

§04

Clinical depth

Renal dose adjustment

No dosage adjustment for mild (eGFR 60-89) or moderate (eGFR 30-59) renal impairment; per label, reduce the dose in severe impairment (eGFR 15-29), where pirtobrutinib exposure rises. ESKD/dialysis data are limited. Hepatic and drug-interaction adjustments apply.

Dialyzability & ESKD dosing

Small molecule, highly protein-bound, hepatically metabolized; dialyzability not well characterized and removal unlikely to be clinically significant. Renal replacement therapy in this setting treats TLS, not drug levels.

Differential diagnosis

TLS crystalline AKI (high uric acid/phosphate, hypocalcemia) vs pre-renal AKI vs nephrotoxin; the urine sediment is bland-to-crystalline, distinguishing it from glomerular or interstitial drug lesions.

Monitoring

Uric acid, potassium, phosphate, calcium and creatinine at initiation in high-burden disease
CBC and tumor burden trend
Blood pressure (class hypertension)

Key trials & series

BRUIN (Mato NEJM 2023) phase I/II in CLL after covalent BTK inhibitors
BRUIN MCL cohort (mantle-cell lymphoma)

Clinical pearls

The renal risk is tumor lysis from effective debulking, not a tubular toxin — risk-stratify and pre-medicate before the first dose.
Pirtobrutinib is often used after covalent-BTK failure in bulky disease — exactly the high-TLS-risk population.
Hydration plus allopurinol (or rasburicase if high risk/elevated urate) prevents most crystalline AKI.
Once TLS is controlled the drug can usually continue — the kidney event is early and self-limited.

Beyond the kidney — non-renal toxicities· 2 organ systems

Class-level context for the major non-renal toxicities of the Non-covalent BTK inhibitor class.

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

Atrial fibrillation, ventricular arrhythmia

Vascular

Hypertension, VTE/ATE, bleeding, aneurysm

Bleeding, hypertension

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2021–2024 · 3 since 2022

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Mar 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

Severe renal impairment (eGFR15-29 mL/min) increases pirtobrutinib exposure [see Clinical Pharmacology ( 12.3 )] . Reduce the JAYPIRCA dosage in patients with severe renal impairment [see Dosage and Administration ( 2.3 )] . No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 823 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 1.88 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
Crystal / Obstructive NephropathyNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Electrolyte Disturbance

ROR 1.8895% CI 1.11–3.19· 14 reports

FAERS outcomes & reporting trend· 25.4% of reports w/ death · 30.6% w/ hospitalization

25.4%

Reported with a death outcome

209 of 823 reports

30.6%

Reported with hospitalization

252 of 823 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 823 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.8895% CI 1.78–4.66· 17 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Renal & urinary

Acute Kidney Injury17

Blood & lymphatic

Anaemia33Pancytopenia32White Blood Cell Count Increased27Platelet Count Decreased25Haemoglobin Decreased20

Immune / infection

Pneumonia66Cytokine Release Syndrome25Covid-1921Sepsis18

General / constitutional

Fatigue20Pyrexia19Pain18

Skin

Rash24

Respiratory

Dyspnoea20

Gastrointestinal

Diarrhoea18

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Pirtobrutinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Ibritumomab tiuxetan

Zevalin · Radioimmunotherapy (Y-90 anti-CD20)

Profile

Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.

PREXTALLYTE

Mild#1 · 87% phenotype match

Cladribine

Leustatin · Purine analog

Profile

Tumor lysis; high-dose nephrotoxicity.

XTALPRELYTE

Mild#2 · 86% phenotype match

Etoposide

Etopophos · Topoisomerase II inhibitor

Profile

Tumor lysis; renally cleared.

XTALPRELYTE

Mild#3 · 86% phenotype match

Hydroxyurea

Hydrea · Ribonucleotide reductase inhibitor

Profile

Tumor lysis in myeloproliferative disease.

XTALPRELYTE

Mild#4 · 86% phenotype match

Nelarabine

Arranon · Purine analog

Profile

Tumor lysis in T-ALL.

XTALPRELYTE

Mild#5 · 86% phenotype match

Pomalidomide

Pomalyst · Immunomodulatory drug (IMiD)

Profile

Tumor lysis; usable in renal impairment.

PRELYTEXTAL

Mild#6 · 86% phenotype match

Compare Pirtobrutinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across BTK inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1AcalabrutinibHTN — HypertensionMild
2ZanubrutinibPRE — Prerenal / Hemodynamic AKIMild
3Pirtobrutinib· this agentXTAL — Crystal / Obstructive NephropathyFAERS AKIMild
4IbrutinibHTN — HypertensionModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.